Engineered Antibodies as Cancer Radiotheranostics
Advanced Science · 2024
DOI: 10.1002/advs.202402361 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, 2024. Verfasst von Zhenni Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore. Hauptthemen laut MEDLINE: Neoplasms, Radioimmunotherapy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National University of Singapore, National Medical Research Council, Singapore Ministry of Education.
Abstract (Originalsprache)
Radiotheranostics is a rapidly growing approach in personalized medicine, merging diagnostic imaging and targeted radiotherapy to allow for the precise detection and treatment of diseases, notably cancer. Radiolabeled antibodies have become indispensable tools in the field of cancer theranostics due to their high specificity and affinity for cancer‐associated antigens, which allows for accurate targeting with minimal impact on surrounding healthy tissues, enhancing therapeutic efficacy while reducing side effects, immune‐modulating ability, and versatility and flexibility in engineering and conjugation. However, there are inherent limitations in using antibodies as a platform for radiopharmaceuticals due to their natural activities within the immune system, large size preventing effective tumor penetration, and relatively long half‐life with concerns for prolonged radioactivity exposure. Antibody engineering can solve these challenges while preserving the many advantages of the immunoglobulin framework. In this review, the goal is to give a general overview of antibody engineering and design for tumor radiotheranostics. Particularly, the four ways that antibody engineering is applied to enhance radioimmunoconjugates: pharmacokinetics optimization, site‐specific bioconjugation, modulation of Fc interactions, and bispecific construct creation are discussed. The radionuclide choices for designed antibody radionuclide conjugates and conjugation techniques and future directions for antibody radionuclide conjugate innovation and advancement are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.
- Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
- Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore.
- Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, 11 Biopolis Way, Helios, Singapore, 138667, Singapore.
- Departments of Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, 119074, Sing…
- Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore, 138673, Singapore.
ORCID-Profile: Xiaoyuan Chen, Jingjing Zhang
Förderung
- National University of Singapore
- National Medical Research Council
- Singapore Ministry of Education
- National Research Foundation
Zitieren
APA
Wei, Z., Li, B., Wen, X., Jakobsson, V., Liu, P., Chen, X., & Zhang, J. (2024). Engineered Antibodies as Cancer Radiotheranostics. Advanced Science. https://doi.org/10.1002/advs.202402361
Vancouver
Wei Z, Li B, Wen X, Jakobsson V, Liu P, Chen X, et al. Engineered Antibodies as Cancer Radiotheranostics. Advanced Science. 2024. doi:10.1002/advs.202402361
BibTeX
@article{Wei2024,
author = {Wei, Zhenni and Li, Bingyu and Wen, Xuejun and Jakobsson, Vivianne and Liu, Peifei and Chen, Xiaoyuan and Zhang, Jingjing},
title = {Engineered Antibodies as Cancer Radiotheranostics},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202402361}
}
EUVIMED